S-1/A: FibroBiologics Files Amendment for Stock Resale: GEM Global Yield and GYBL to Offer 1.5 Million Shares

FibroBiologics files an amendment to its S-1 registration statement to register the resale of approximately 1.5 million shares of common stock by GEM Global Yield LLC SCS and GEM Yield Bahamas Limited.

Summary

• FibroBiologics has filed an amendment to its Form S-1 registration statement to register the resale of 1,526,840 shares of its common stock.
• The shares are to be offered by GEM Global Yield LLC SCS (GEM) and GEM Yield Bahamas Limited (GYBL).
• The registration covers 227,057 shares sold to GEM and 1,299,783 shares underlying warrants issued to GYBL.
• These registration rights were granted in connection with a share purchase agreement dated November 12, 2021.
• On January 31, 2024, FibroBiologics issued a draw-down notice under the GEM SPA to have GEM purchase up to 900,000 shares at a threshold price of $15.00 per share.
• GEM purchased 65,447 shares and 76,851 shares at $13.50 per share, resulting in net cash proceeds of approximately $1.9 million.
• FibroBiologics then authorized a reduction of the draw-down threshold price to no less than $13.50 per share, and GEM purchased 84,759 shares at $12.15 per share for net cash proceeds of approximately $1.0 million.
• GYBL received a warrant to purchase 1,299,783 shares at an initial exercise price of $21.54 per share.
• GEM and GYBL may sell the shares publicly or through private transactions at prevailing market prices or negotiated prices.
• FibroBiologics will not receive any proceeds from the sale of these shares by the Registered Stockholders.
• A 1-for-4 reverse stock split was approved on October 6, 2023, and effected on October 31, 2023, with all share and per share information adjusted accordingly.
• Pete O'Heeron, the founder and CEO, beneficially owns approximately 60% of the voting power, making FibroBiologics a controlled company.
• The company is an emerging growth company and a smaller reporting company, allowing for reduced reporting requirements.

Sentiment

Score: 5

Explanation: Neutral. This is a standard filing for a stock resale, with both positive and negative aspects. The company gains access to capital, but existing shareholders may experience dilution.

Negatives

• FibroBiologics will not receive any proceeds from the sale of shares by the Registered Stockholders.
• The listing of the common stock on Nasdaq, without a firm-commitment underwritten offering, may lead to more volatile trading volume and price.
• The company is a controlled company, which may reduce corporate governance protections for shareholders.
• The company has identified a material weakness in its internal controls over financial reporting due to lack of segregation of duties.

Risks

• The Registered Stockholders may, or may not, elect to sell their shares of common stock covered by this prospectus, as and to the extent they may determine.
• An active trading market may not develop or continue to be liquid and the market price of our shares of common stock may be volatile.
• The requirements of being a public company may strain our resources, divert management's attention and affect our ability to attract and retain executive management and qualified board members.
• We have identified a material weakness in our internal controls over financial reporting due to lack of segregation of duties.

Future Outlook

The Registered Stockholders may, or may not, elect to sell their shares of common stock covered by this prospectus, as and to the extent they may determine.

Industry Context

This announcement is typical for companies that have agreements with investment funds like GEM, where the fund provides capital in exchange for shares that they can then resell into the market. The filing allows GEM to sell its shares, but it doesn't obligate them to do so.

Comparison to Industry Standards

• The agreement with GEM is similar to structured equity lines used by other small-cap biotech companies to access capital.
• The warrant issuance is a common incentive for the investor providing the capital commitment.

Stakeholder Impact

• Existing shareholders may experience dilution if the Registered Stockholders sell their shares.
• The company's access to capital may be improved through the GEM SPA.

Next Steps

• The Registered Stockholders may offer, sell or distribute all or a portion of the shares of common stock hereby registered publicly or through private transactions at prevailing market prices or at negotiated prices or through any other means described in the section entitled Plan of Distribution herein.

Key Dates

Keywords

FibroBiologics, GEM Global Yield LLC SCS, GEM Yield Bahamas Limited, stock resale, common stock, warrants, registration statement, FBLG, share purchase agreement, direct listing